BioMarin (BMRN) Positive Drug Study Data
Post# of 106
Posted On: 06/18/2015 7:05:40 AM
Shares of BioMarin Pharmaceutical Inc. (BMRN) surged more than 6% in extended-hours trading Wednesday after the company reported positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide) in children with achondroplasia, the most common form of human dwarfism characterized by failure of normal conversion of cartilage into bone, which results in disproportionate short stature.
BMRN's BMN 111 was well tolerated across all three dose cohorts. In children receiving the highest dose of 15 micrograms per kilogram daily, the study results showed a 50% increase in mean annualized growth velocity compared to their own natural history control growth velocity. According to BMRN, this increase in growth velocity, if maintained, could allow children with achondroplasia to resume a normalized growth rate.
BMRN's BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide, has Orphan designation in both the United States and Europe. Currently there is no FDA-approved treatment for achondroplasia.
BMRN develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
More about BioMarin Pharmaceutical Inc. (BMRN) at www.BMRN.com.
**
After the closing bell on Wednesday, Crossroads Systems, Inc. (CRDS) provided an update to its patent infringement litigation against defendants Oracle, NetApp, Cisco, Quantum, Dot Hill, and Huawei.
CRDS is seeking monetary damages for infringement of U.S. patents 6,425,035, 7,051,147, 7,934,041, and 7,987,311.
CRDS said that the Federal Court in the Western District of Texas entered an order in which the Court determined the meaning of 17 disputed claim terms in the patents-in-suit. A Markman order is significant to a patent case because it provides clarity to a number of patent infringement and validity arguments and must be followed by a jury in deliberations.
According to CRDS, the judge's Markman ruling confirms its belief that the defendants are infringing its intellectual property and strengthens the company's resolve to recover the hundreds of millions of dollars CRDS believes could be due its shareholders
CRDS is a global provider of data storage solutions.
More about Crossroads Systems, Inc. (CRDS) at www.crossroads.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites CRWE PR, expected to be a one-stop shop for the various needs of consumers.
CRWE PR Network's business model is based on selling advertising to businesses targeting both locally and nationally
CRWE‘s Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website network and partnership with CRWE PR.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
BMRN's BMN 111 was well tolerated across all three dose cohorts. In children receiving the highest dose of 15 micrograms per kilogram daily, the study results showed a 50% increase in mean annualized growth velocity compared to their own natural history control growth velocity. According to BMRN, this increase in growth velocity, if maintained, could allow children with achondroplasia to resume a normalized growth rate.
BMRN's BMN 111 (vosoritide), an analog of C-type Natriuretic Peptide, has Orphan designation in both the United States and Europe. Currently there is no FDA-approved treatment for achondroplasia.
BMRN develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
More about BioMarin Pharmaceutical Inc. (BMRN) at www.BMRN.com.
**
After the closing bell on Wednesday, Crossroads Systems, Inc. (CRDS) provided an update to its patent infringement litigation against defendants Oracle, NetApp, Cisco, Quantum, Dot Hill, and Huawei.
CRDS is seeking monetary damages for infringement of U.S. patents 6,425,035, 7,051,147, 7,934,041, and 7,987,311.
CRDS said that the Federal Court in the Western District of Texas entered an order in which the Court determined the meaning of 17 disputed claim terms in the patents-in-suit. A Markman order is significant to a patent case because it provides clarity to a number of patent infringement and validity arguments and must be followed by a jury in deliberations.
According to CRDS, the judge's Markman ruling confirms its belief that the defendants are infringing its intellectual property and strengthens the company's resolve to recover the hundreds of millions of dollars CRDS believes could be due its shareholders
CRDS is a global provider of data storage solutions.
More about Crossroads Systems, Inc. (CRDS) at www.crossroads.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites CRWE PR, expected to be a one-stop shop for the various needs of consumers.
CRWE PR Network's business model is based on selling advertising to businesses targeting both locally and nationally
CRWE‘s Curbiz ( www.curbiz.com ), in development stage, is an online business directory connecting people with local, state, country and global businesses. Curbiz will provide local advertising services, including free and paid business listing services to businesses of various sizes, as well as enable businesses to deliver targeted search advertising to large local audiences through its Website network and partnership with CRWE PR.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)BioMarin Pharmaceutical Inc. (BMRN) Stock Research Links
Scroll down for more posts ▼